Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension

Williams, Bryan, (ESC Chairperson) (UK); Mancia, Giuseppe, (ESH Chairperson) (Italy); Spiering, Wilko, (The Netherlands); Rosei, Enrico Agabiti, (Italy); Azizi, Michel, (France); Burnier, Michel, (Switzerland); Clement, Denis, (Belgium); Coca, Antonio, (Spain); De Simone, Giovanni, (Italy); Dominiczak, Anna, (UK); Kahan, Thomas, (Sweden); Mahfoud, Felix, (Germany); Redon, Josep, (Spain); Ruilope, Luis, (Spain); Zanchetti, Alberto; Kerins, Mary, (Ireland); Kjeldsen, Sverre, (Norway); Kreutz, Reinhold, (Germany); Laurent, Stephane, (France); Lip, Gregory Y.H., (UK); McManus, Richard, (UK); Narkiewicz, Krzysztof, (Poland); Ruschitzka, Frank, (Switzerland); Schmieder, Roland, (Germany); Shlyakhto, Evgeny, (Russia); Tsioufis, Konstantinos, (Greece); Aboyans, Victor, (France); Desormais, Ileana, (France) List of authors/Task Force members:

doi: 10.1097/HJH.0000000000001961
PRACTICE GUIDELINES

Correspondence to Professor Michel Burnier, Service of Nephrology and Hypertension, Rue du Bugnon 17, Lausanne 1011, Switzerland. E-mail: michel.burnier@chuv.ch

Abbreviations: ABI, ankle–brachial index; ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ACEi, angiotensin-converting enzyme inhibitor; ACR, albumin:creatinine ratio; ARB, angiotensin receptor blocker; BP, blood pressure; bpm, beats per minute; BSA, body surface area; CAD, coronary artery disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DHP, dihydropyridine; eGFR, estimated glomerular filtration rate; ESC, European Society of Cardiology; ESH, European Society of Hypertension; HbA1c, Haemoglobin A1c; HBPM, home blood pressure monitoring; HDL-C, HDL-cholesterol; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HMOD, hypertension-mediated organ damage; IMT, intima–media thickness; LDLC, LDL cholesterol; LEAD, lower extremity artery disease; LVH, left ventricular hypertrophy; MAP, mean arterial pressure; MI, myocardial infarction; MR, magnetic resonance; MRA, mineralocorticoid receptor antagonist; MUCH, masked uncontrolled hypertension; NTproBNP; N-terminal pro-B natriuretic peptide; o.d., omni die (every day); PAC, plasma aldosterone concentration; PAD, peripheral artery disease; PRA, plasma renin activity; PRC, plasma renin concentration; PWV, pulse wave velocity; RAS, renin–angiotensin system; RCT, randomized controlled trial; RWT, relative wall thickness; SPC, single-pill combination; SUCH, sustained uncontrolled hypertension; TIA, transient ischaemic attack; WUCH, white-coat uncontrolled hypertension

† Professor Zanchetti died during the development of these Guidelines, in March 2018. He contributed fully to the redaction of these Guidelines, as a member of the Guidelines’ Task Force and as a section co-ordinator. He will be sadly missed by colleagues and friends.

Received 5 September, 2018

Accepted 11 September, 2018

ESH Practice Guidelines Writing Task Force: Michel Burnier, Sverre E. Kjeldsen, Guido Grassi, Krzysztof Narkiewicz, Gianfranco Parati, Reinhold Kreutz, Enrico Agabiti Rosei, Konstantinos Tsioufis, Bryan Williams, Giuseppe Mancia.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.